Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

MLA

Okada, Hideho, et al. “Induction of Robust Type-I CD8+ T-Cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 21, no. 2, Jan. 2015, pp. 286–94. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-14-1790.

APA

Okada, H., Butterfield, L. H., Hamilton, R. L., Hoji, A., Sakaki, M., Ahn, B. J., Kohanbash, G., Drappatz, J., Engh, J., Amankulor, N., Lively, M. O., Chan, M. D., Salazar, A. M., Shaw, E. G., Potter, D. M., & Lieberman, F. S. (2015). Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(2), 286–294. https://doi.org/10.1158/1078-0432.CCR-14-1790

Chicago

Okada, Hideho, Lisa H Butterfield, Ronald L Hamilton, Aki Hoji, Masashi Sakaki, Brian J Ahn, Gary Kohanbash, et al. 2015. “Induction of Robust Type-I CD8+ T-Cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 21 (2): 286–94. doi:10.1158/1078-0432.CCR-14-1790.